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What is the addiction risk
associated with tramadol?
■ EVIDENCE-BASED ANSWER
Tramadol (Ultram, generic and with acetamino-
phen in Ultracet) carries a risk of substance abuse
(strength of recommendation [SOR]: B, based on
case report surveillance programs). While it
appears that tramadol’s risk of substance abuse is
low (SOR: B, based on case report surveillance
programs), tramadol is associated with a with-
drawal syndrome usually typical of opioid with-
drawal (SOR: B, based on case report surveillance
programs, and a prospective descriptive study). 
■ EVIDENCE SUMMARY
Tramadol is a novel, central-acting synthetic opioid
with weak mu-opioid activity, and is approved for
treatment of moderate to moderately severe pain in
adults. Anecdotally, some clinicians have assumed
this popular analgesic’s nonscheduled status under
the Controlled Substance Act (CSA) means tramadol
has no substance abuse potential. (The term “abuse”
herein denotes substance abuse or dependence.) 
Evidence of tramadol abuse in the US comes pri-
marily from federally operated programs collecting
adverse drug event (ADE) data. The MedWatch pro-
gram of the Food and Drug Administration (FDA)
provides a central depository for receiving and com-
piling postmarketing voluntary case reports. While
passive reporting systems can significantly under-
estimate serious ADE numbers, these reports are
often the first evidence of an ADE after a new drug’s
release into the market.1 MedWatch has received
766 case reports of abuse associated with tramadol,
as well as 482 cases of withdrawal associated with
tramadol from the drug’s initial US marketing in
1995 through September 2004.2,3
The Drug Abuse Warning Network (DAWN) is
a federally operated, national surveillance system
that monitors trends in drug-related emergency
department visits. Over the period from 1995 to
2002, DAWN reported drug-related emergency
department visits mentioning tramadol in more
than 12,000 cases. Tramadol case numbers sig-
nificantly increased 165% during this time. For
perspective, during the same period, DAWN found
nalbuphine (Nubain, also not CSA scheduled) in
118 cases, propoxyphene drug combinations (CSA
Class IV) in more than 45,000 cases, codeine drug
combinations (CSA Classes III & V) in about
50,000 cases, and hydrocodone drug combina-
tions (CSA Class III) in around 128,000 cases.4
Using data from observational postmarketing
studies, investigators have extrapolated a tra-
madol abuse rate for the general tramadol-
exposed population.5,6 Ortho-McNeil, Ultram’s
manufacturer, funded a surveillance program that
compiled tramadol abuse and withdrawal case
reports from 2 sources: (1) periodic surveys for
tramadol abuse case reports from a group of 255
substance abuse experts studying and caring for
addiction communities, and (2) voluntary ADE
case reports from health care professionals and
consumers received by Ortho-McNeil. Over 3
years of surveillance, the program received 454
case reports classified as tramadol abuse. Over 5
years of surveillance, 422 cases of substance
withdrawal, with primarily opioid withdrawal
symptoms, were reported. There are significant
threats to the validity and generalizability of the
investigators’ estimated abuse rate of 1 to 3 cases
per 100,000 tramadol-exposed patients. The
abuse cases were collected in nonrepresentative
samples of the tramadol-exposed population.
Tramadol exposure is likely suppressed in addic-
tion communities with access to preferred, more
potent or euphoriant opioids than tramadol.
Voluntary case reports of tramadol abuse signifi-
cantly underestimate the actual number of abuse
cases in the tramadol-exposed population. In
addition, the low survey return rate (49%) further
decreases the accuracy of any estimation of tra-
madol abuse rates.
Prospective studies among patients with
known abuse, or at high risk of abuse, reported a
tramadol abuse rate, as well as subjective experi-
ences of tramadol withdrawal. A 3-year post-mar-
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keting cohort study measured tramadol’s nonmed-
ical misuse rates using urine drug testing for tra-
madol among 1601 participants in 4 US state mon-
itoring programs for impaired healthcare profes-
sionals.7 Tramadol exposure occurred in 140
(8.7%) participants. Thirty-nine (28%) were clas-
sified as extensive experimentation or abuse of tra-
madol. Overall, the rate of extensive experimenta-
tion or abuse was 18 cases per thousand person-
years. The Hawthorne effect, where awareness of
being monitored alters a subject’s behavior, may
threaten these measured frequency rates’ general-
izability. Another prospective study assessed the
subjective tramadol withdrawal experience in 219
patients with a diagnosis of “Tramadol misuse”
who were attending 6 drug detoxification centers
in China.8 Validated drug dependence symptom
scales found that while the degree of physical
dependence reported was uniformly mild, the
majority of patients reported the psychic depend-
ence symptom of tramadol craving.
The FDA’s Drug Abuse Advisory Committee
performed a formal review of the tramadol abuse
evidence in 1998, including the data from Ortho-
McNeil’s surveillance studies and federal case
reporting/surveillance programs. The FDA did not
recommend changing tramadol’s unscheduled sta-
tus.9 The FDA’s considered decision to not sched-
ule tramadol as a controlled substance implies its
abuse risk to the general population is low in com-
parison to its novel analgesic benefit. 
■ RECOMMENDATIONS FROM
OTHERS
Ortho-McNeil’s revised 2001 product package
insert for Ultram states, “Tramadol may induce
psychic and physical dependence of the morphine
type (mu-opioid). Dependence and abuse, including
drug-seeking behavior and taking illicit actions to
obtain the drug are not limited to those patients with
prior history of opioid dependence” (italics in origi-
nal, emphasizing 2001 addition). The risk for
patients with a history of substance abuse has
been observed to be higher.10
Todd McDiarmid, MD, Leslie Mackler, MSLS,
Moses Cone Health System, Greensboro, NC
■ CLINICAL COMMENTARY
Though it may not have high abuse
potential, prescribe tramadol cautiously
Although tramadol appears to have a low poten-
tial for abuse, the literature does reveal evi-
dence of abuse, addiction, and withdrawal, even
in patients without a history of such problems.
We do not know if tramadol is less addictive
than other narcotics in high-risk patients.  For
patients at risk for dependence, tramadol is a
reasonable alternative to other opioids, but
abuse appears more likely in these patients.
Tramadol may be most appropriate for treat-
ment of acute painful conditions, but it can be
administered chronically under a watchful eye.
Providers should prescribe it cautiously, partic-
ularly in patients with a history of abuse or
addiction, at least until more definitive evidence
surfaces.
David M. Schneider, MD, Sutter Medical Center Family
Practice Residency Program, Santa Rosa, Calif
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What are the indications 
for evaluating a patient 
with cough for pertussis?
■ EVIDENCE-BASED ANSWER
Pertussis should be considered in infants with
apnea or severe coughing illnesses of any dura-
tion, and in older children or adults with pro-
longed cough (eg, longer than 2 weeks), especial-
ly if accompanied by inspiratory whoop or house-
hold exposure to a prolonged cough illness
(strength of recommendation [SOR]: B, based on
consecutive cohort studies with poor reference
standards). Coughing paroxysms, posttussive
vomiting, and absence of fever, while typical of
pertussis, are of little help in distinguishing it
from other causes of prolonged coughing illnesses
(SOR: B, based on consecutive cohort studies
with poor reference standards). 
■ EVIDENCE SUMMARY
Pertussis is an important cause of cough in all
age groups. Ten prevalence studies of adoles-
cents and adults seeking medical attention for a
prolonged cough (defined variously as >1–4
weeks) found acute pertussis in 12% to 32%.1
While cough longer than 2 weeks, inspiratory
whoop, posttussive vomiting, coughing parox-
ysms, and absence of fever are commonly associ-
ated with pertussis, relatively few studies have
assessed the sensitivities and specificities of
these symptoms. The Table summarizes results
from 5 cohort series of children and adults with
laboratory-confirmed pertussis. Comparison
groups were variously defined by negative per-
tussis cultures, negative pertussis serology, or
serologic confirmation of other respiratory infec-
tions. Likelihood ratios (LR) were calculated
from the data presented in each paper.
The magnitude and variability of these likeli-
hood ratios suggest that individual symptoms may
be of limited help in distinguishing pertussis from
other causes of prolonged cough. Combinations of
symptoms may be slightly more helpful. In a study
comparing 10 patients with culture-confirmed per-
tussis with 10 patients with serologically con-
firmed mycoplasma pneumonia, the combination of
cough >14 days and whoop had a sensitivity of
80%, a positive LR (LR+) of 8 and a negative LR
(LR–) of 0.22.2 A cohort series of children aged <5
years with suspected pertussis compared 33 with
positive cultures to 55 with negative cultures. The
constellation of spasmodic cough and lymphocyto-
sis (>10,000) had a sensitivity of 83%, a LR+ of
2.5, and a LR– of 0.25. Cough >14 days with
whoop and vomiting had a sensitivity of 67%, a
LR+ of 3.2, and LR– of 0.42.3
Infants aged <6 months with pertussis are at par-
ticular risk for atypical presentations and serious
complications. In a US series of 18,500 infants with
pertussis, apnea was seen in 64% of infants under 1
month and in 44% between 6 and 11 months. Forty
percent of the 6- to 11-month-olds had received at
least 3 doses of pertussis vaccine.4 A British study of
126 infants aged <5 months admitted to the pedi-
atric intensive care unit with apnea, bradycardia, or
respiratory failure found that 20% had pertussis.
Apnea as a predictor of pertussis had a sensitivity of
68% and a specificity of 60%.5
Pertussis should be considered early in the
evaluation of young infants with cough. In a case-
control study comparing 15 fatal cases of pertus-
sis with 32 who survived (infants aged <6
months), the mean number of days from symptom
onset to hospital admission were 5.3 (fatal) and
8.6 (survivors). Rates of apnea on admission were
40% and 52%.6 A case series of 9 infants aged <7
weeks requiring admission to an intensive care
unit for pertussis found that 8 had been sick for
less than 4 days at the time of admission. All 9
presented with poor feeding and cough, and 5 had
experienced apnea.7
■ RECOMMENDATIONS FROM
